Experimental nanoparticle research targeting prostate cancer in laboratory models, exploring immune-focused strategies and implications for future therapies.
Key Takeaways
- Engineered silica nanoparticles induced tumor cell ferroptosis and myeloid reprogramming in mouse models
- Combination with checkpoint immunotherapy produced complete remissions in multiple treated mice
- Nanoparticles reprogrammed TLR–ferroptosis signaling and immunometabolic pathways to overcome myeloid suppression